PagrindinisRDY • NYSE
add
Dr Reddy's Laboratories Ltd
Ankstesnė uždarymo kaina
13,99 $
Dienos intervalas
14,12 $ - 14,30 $
Metų intervalas
12,90 $ - 16,89 $
Bendroji vertė rinkoje
11,98 mlrd. USD
Vidutinė prekybos apimtis
844,76 tūkst.
Aktualios naujienos
Finansiniai rodikliai
Pajamų ataskaita
Pajamos
Grynosios pajamos
(INR) | 2024-09info | Metinis pokytis |
---|---|---|
Pajamos | 80,16 mlrd. | 16,51 % |
Veiklos sąnaudos | 29,72 mlrd. | 24,54 % |
Grynosios pajamos | 12,55 mlrd. | −15,18 % |
Grynojo pelno marža | 15,66 | −27,20 % |
Pelnas tenkantis vienai akcijai | 15,83 | −11,13 % |
EBITDA | 22,02 mlrd. | 8,53 % |
Taikomas mokesčio tarifas | 30,01 % | — |
Balansas
Visas turtas
Visi įsipareigojimai
(INR) | 2024-09info | Metinis pokytis |
---|---|---|
Lėšos, trump. investicijos | 63,07 mlrd. | −7,15 % |
Visas turtas | 465,96 mlrd. | 34,27 % |
Visi įsipareigojimai | 156,67 mlrd. | 66,79 % |
Visos paprastosios akcijos | 309,28 mlrd. | — |
Išleistos akcijos | 833,05 mln. | — |
Kaina / apskaitinė vertė | 0,04 | — |
Turto grąža | 10,24 % | — |
Kapitalo grąža | 13,21 % | — |
Pinigų srautas
Grynasis pokytis (grynaisiais pinigais)
(INR) | 2024-09info | Metinis pokytis |
---|---|---|
Grynosios pajamos | 12,55 mlrd. | −15,18 % |
Pinigai iš operacijų | 9,32 mlrd. | −48,03 % |
Pinigai iš investicijų | −19,07 mlrd. | −322,21 % |
Pinigai iš finansavimo | 16,15 mlrd. | 329,53 % |
Grynasis pokytis (grynaisiais pinigais) | 6,37 mlrd. | 1,03 % |
Laisvas pinigų srautas | 3,92 mlrd. | −72,47 % |
Apie
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Generalinis direktorius
Įkurta
1984
Pagrindinė būstinė
Svetainė
Darbuotojų skaičius
27 048